BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 3, 2026
Home » Blogs » BioWorld MedTech Perspectives » Screening saves lives, but criteria too narrow

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Diagnostics / Imaging / Oncology

Screening saves lives, but criteria too narrow

Aug. 2, 2013
By Amanda Pedersen

CTA few years back my brother-in-law Sam was starting a new job and was required to get a physical as part of the hiring process. A standard X-ray revealed a spot on his lungs and further testing confirmed it was cancer. The diagnosis came about two years after he’d quit smoking, but he had been a smoker for many years and was somewhere in his early 40s. Thankfully, because it was caught and treated so early, he is still with us today and doing great. But what if he hadn't had that physical? Earlier this week the U.S. Preventive Services Task Force issued a draft recommendation giving its second highest approval rating for routine CT screening for those at high risk for lung cancer. The grade B recommendation was widely applauded by advocacy groups such as the Lung Cancer Alliance, the American College of Radiology, and the Prevent Cancer Foundation. If approved in final form, the recommendation will trigger Medicare and insurance coverage and bring about a dramatic drop in lung cancer deaths. Experts say as many as 20,000 deaths a year could be prevented by screening. Naturally my first thought when I heard about the recommendation was my brother-in-law and all the people like him who could be saved by this move. But the recommendation only applies to current and former smokers age 55 to 80 with a smoking history the equivalent of smoking a pack a day for 30 years or two packs a day for 15 years. My brother-in-law would have been too young to meet that criteria at the time that he was diagnosed. How many other current and former smokers would slip through the cracks? How many of them could be saved by screening if the age range of the recommendation was widened? I don’t claim to be an expert on lung cancer but it seems the criteria needs to be broadened. At least one advocacy group agrees. Legacy, a group that says it supports the task force recommendations but takes issue with some of the specifics, says the age range is too narrow. According to the Lung Cancer Alliance, lung cancer takes 160,000 lives a year. Only 15% of people diagnosed with lung cancer will live five years or longer, primarily because the vast majority of lung cancers are diagnosed at a late stage. Sam was one of the lucky few, but he could have easily been one of the unlucky thousands, had it not been for that one physical that prompted additional screening. Screening saves lives. The task force made an important decision when it issued its draft recommendation, but it would be even better if the minimum age for routine screening was lowered to 40.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 2, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • Illustration of brain with neuron receptor

    5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

    BioWorld Science
    Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing